Curated News
By: NewsRamp Editorial Staff
October 29, 2026
TransCode Therapeutics Launches Strategic Review to Maximize Value
TLDR
- TransCode Therapeutics launched a strategic review to maximize value from its oncology portfolio, including lead candidate TTX-MC138, with Tungsten Advisors as exclusive adviser.
- The review will assess licensing, sales, partnerships, and business combinations for TransCode's RNA-based candidate TTX-MC138, now in Phase 2a for colorectal cancer.
- TransCode's strategic review aims to advance RNA-based cancer therapies, potentially improving outcomes for patients with high-risk and advanced cancers.
- TTX-MC138 targets microRNA-10b, a biomarker of metastasis, and is being tested in circulating tumor DNA-positive colorectal cancer patients after curative-intent therapy.
Impact - Why it Matters
This strategic review signals a critical juncture for TransCode Therapeutics as it explores options to unlock value from its promising RNA-based oncology portfolio. For investors, the outcome could mean accelerated development or a lucrative partnership for TTX-MC138, a potential first-in-class therapy for metastatic cancers. For patients, any strategic move could expedite access to innovative treatments for high-risk colorectal cancer and other microRNA-10b overexpressing tumors. The involvement of Tungsten Advisors underscores the seriousness of the process, which may attract big pharma interest and validate the company's approach. As the biotech landscape evolves, TransCode's decisions will be watched closely by stakeholders across the healthcare spectrum.
Summary
TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage biopharmaceutical company developing RNA-based therapeutics and immuno-oncology treatments for high-risk and advanced cancers, has announced that its board of directors has initiated a formal strategic process to evaluate opportunities to maximize the value of the company and its oncology portfolio, including lead product candidate TTX-MC138. The review will consider potential licensing or sales of individual assets, development and commercialization partnerships, portfolio transactions, business combinations, and other strategic alternatives. TransCode has engaged Tungsten Advisors as its exclusive strategic financial adviser for the process.
TTX-MC138, an investigational RNA-based therapeutic targeting microRNA-10b, has advanced into Phase 2a clinical development following a Phase 1a study that provided initial safety data and reports of stable disease. The ongoing trial is evaluating the treatment in patients with circulating tumor DNA-positive colorectal cancer following curative-intent therapy, in collaboration with Quantum Leap Healthcare Collaborative. TransCode also recently announced a collaboration with Natera Inc. to use its Signatera test to identify eligible patients and support trial enrollment. Chairman and CEO Philippe P. Calais said the strategic review is intended to identify opportunities to advance the company’s oncology programs while seeking to maximize stockholder value. TransCode cautioned that the process may not result in a transaction or other strategic outcome.
To view the full press release, visit https://ibn.fm/AGxas
About TransCode Therapeutics
TransCode Therapeutics is a clinical stage company pioneering immuno-oncology and RNA therapeutic treatments for high risk and advanced cancers. The company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
NOTE TO INVESTORS: The latest news and updates relating to RNAZ are available in the company’s newsroom at https://ibn.fm/RNAZ
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
[email protected]
BioMedWire is powered by IBN
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, TransCode Therapeutics Launches Strategic Review to Maximize Value
